Laman UtamaRDY • NYSE
add
Dr Reddy's Laboratories Ltd
$14.20
Selepas Waktu Dagangan:(0.00%)0.00
$14.20
Tutup: 22 Nov, 4:08:36 PTG GMT-5 · USD · NYSE · Penafian
Tutup sebelumnya
$13.99
Julat hari
$14.12 - $14.30
Julat tahun
$12.90 - $16.89
Permodalan pasaran
11.98B USD
Bilangan Purata
844.76K
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(INR) | Sep 2024info | Perubahan T/T |
---|---|---|
Hasil | 80.16B | 16.51% |
Perbelanjaan pengendalian | 29.72B | 24.54% |
Pendapatan bersih | 12.55B | -15.18% |
Margin untung bersih | 15.66 | -27.20% |
Pendapatan bagi setiap syer | 15.83 | -11.13% |
EBITDA | 22.02B | 8.53% |
Kadar cukai berkesan | 30.01% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(INR) | Sep 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 63.07B | -7.15% |
Jumlah aset | 465.96B | 34.27% |
Jumlah liabiliti | 156.67B | 66.79% |
Jumlah ekuiti | 309.28B | — |
Syer tertunggak | 833.05J | — |
Harga kepada buku | 0.04 | — |
Pulangan pada aset | 10.24% | — |
Pulangan pada modal | 13.21% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(INR) | Sep 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | 12.55B | -15.18% |
Tunai daripada operasi | 9.32B | -48.03% |
Tunai daripada pelaburan | -19.07B | -322.21% |
Tunai daripada pembiayaan | 16.15B | 329.53% |
Perubahan bersih dalam tunai | 6.37B | 1.03% |
Aliran tunai bebas | 3.92B | -72.47% |
Perihal
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Diasaskan
1984
Ibu pejabat
Tapak web
Pekerja
27,048